Abstract
First isolated and characterized over 60 years ago, strains of Bifidobacterium bifidum have been extensively studied and many characterized in detail at a molecular level over the subsequent decades. Several properties of potential clinical significance have been identified in the laboratory: immune-modulatory, metabolic, antibacterial, and antiviral. Clinical trials in man have revealed positive effects in diarrheal disease, disorders involving mucosal inflammation of the gastrointestinal tract, and functional gastrointestinal disorders.
| Original language | English (US) |
|---|---|
| Title of host publication | The Microbiota in Gastrointestinal Pathophysiology |
| Subtitle of host publication | Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis |
| Publisher | Elsevier |
| Pages | 131-133 |
| Number of pages | 3 |
| ISBN (Electronic) | 9780128040621 |
| ISBN (Print) | 9780128040249 |
| DOIs | |
| State | Published - Jan 1 2017 |
Keywords
- BGN4 and PRL 2010
- Bacteriocin
- BbVK3
- Bifidobacterium bifidum
- Bifidobacterium bifidum strains BB-06
- Diarrhea
- G9-1
- Genome
- Immunity
- Irritable bowel syndrome
- Mimbb-75
- NCFB 1454
- Pilus
- R0071
- YIT 4007
- YIT-10347
ASJC Scopus subject areas
- Medicine(all)